J Korean Med Sci.
2003 Oct;18(5):673-678. 10.3346/jkms.2003.18.5.673.
High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study
- Affiliations
-
- 1Department of Internal Medicine, Gachon Medical School, Korea. smbang@hanmail. net
- 2Department of Internal Medicine, University of Ulsan Medical School.
- 3Department of Internal Medicine, Sungkyunkwan University School of Medicine.
- 4Department of Internal Medicine, Ehwa Women's University College of Medicine.
- 5Department of Internal Medicine, Kyunghee University College of Medicine.
- 6Department of Internal Medicine, Korean Cancer Center Hospital.
- 7Department of Internal Medicine, Seoul National University College of Medicine.
- 8Department of Internal Medicine, Hanyang University College of Medicine.
- 9Department of Internal Medicine, Hallym University College of Medicine.
- 10Department of Internal Medicine, Pochon CHA University College of Medicine.
- 11Department of Internal Medicine, Ajou University College of Medicine.
- 12Department of Internal Medicine, Chung-Ang University College of Medicine.
- 13Department of Internal Medicine, Chungnam National University College of Medicine, Korea.
- KMID: 1130037
- DOI: http://doi.org/10.3346/jkms.2003.18.5.673
Abstract
- We conducted a phase II multicenter trial to estimate the response and survival of patients with newly diagnosed multiple myeloma to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible patients who had undergone induction with vincristine, adriamycin and dexamethasone (VAD) should have adequate cardiac, pulmonary and renal function (creatinine <2 mg/dL). Melphalan at 200 mg/m2 was used as a conditioning regimen. Eighty patients were enrolled from 13 centers. The median age of the patients was 53 yr (range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 patients, respectively. Beta2-microglobulin, CRP and LDH were increased in 74, 42 and 34% of the patients examined. Cytogenetic data were available in 30 patients, and 6 patients showed numeric or structural abnormalities. Two therapy-related mortalities occurred from infection. Among the 78 evaluable patients, CR/PR/MR/NC/PD were achieved in 48/26/2/1/1patients, respectively. After a median follow-up of 30 months, the median overall and event-free survivals were 66 months (95% CI: 20-112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed multiple myeloma.
MeSH Terms
-
Adult
Aged
Antigens, CD34/biosynthesis
Antineoplastic Agents, Alkylating/*therapeutic use
C-Reactive Protein/biosynthesis
Cell Survival
Combined Modality Therapy
Cytogenetics
Disease-Free Survival
Female
Human
Korea
L-Lactate Dehydrogenase/biosynthesis
Male
Melphalan/*therapeutic use
Middle Aged
Multiple Myeloma/*therapy
Peripheral Blood Stem Cell Transplantation/*methods
Time Factors
Transplantation, Autologous/*methods
beta 2-Microglobulin/blood
Cited by 3 articles
-
A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
Keun-Wook Lee, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, Soo-Mee Bang, Jae Hoon Lee, Seung Tae Lee, Jee Hyun Kim, Sung-Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim
J Korean Med Sci. 2005;20(4):598-602. doi: 10.3346/jkms.2005.20.4.598.Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience
Il-Young Jang, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Kwang-Kuk Kim, Young-Min Lim, Won-Ki Min, Cheolwon Suh
Blood Res. 2014;49(1):42-48. doi: 10.5045/br.2014.49.1.42.Epidemiological Change of Multiple Myeloma in Korea
Jae Hoon Lee, Soo-Mee Bang
Korean J Hematol. 2006;41(4):225-234. doi: 10.5045/kjh.2006.41.4.225.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Efficacy of High-dose Melphalan with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
- A Case of Scleroderma following Autologous Peripheral Stem Cell Transplantation
- The Evolving Role of Myeloablative Chemotherapy with Stem Cell Transplantation for the Treatment of Autoimmune Disease
- Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report
- HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT
